Literature DB >> 12062339

Ablation therapy for atrial fibrillation (AF): past, present and future.

Pierre Jaïs1, Rukshen Weerasooriya, Dipen C Shah, Mélèze Hocini, Laurent Macle, Kee-Joon Choi, Christophe Scavee, Michel Haïssaguerre, Jacques Clémenty.   

Abstract

Atrial fibrillation, the most common arrhythmia, is frequently disabling and drug resistant. Non-pharmacological approaches including surgery and catheter-based ablation have been developed for the most symptomatic patients. These new treatment strategies have dramatically increased our knowledge of the pathophysiology of this arrhythmia but most importantly demonstrated that atrial fibrillation is curable. These approaches are far from being perfect but good enough to be offered in routine practice to selected patients in experienced centers. The importance of pulmonary veins in the initiation of AF has clearly been demonstrated and their role in maintaining AF is likely. Most of the curative approaches are therefore based on their isolation. Future technical improvements based on presently applied concepts are likely to widen the indications for ablation therapy of AF.

Entities:  

Mesh:

Year:  2002        PMID: 12062339     DOI: 10.1016/s0008-6363(02)00263-8

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  12 in total

1.  MEMS-Based Flexible Force Sensor for Tri-Axial Catheter Contact Force Measurement.

Authors:  Hardik J Pandya; Jun Sheng; Jaydev P Desai
Journal:  J Microelectromech Syst       Date:  2016-12-22       Impact factor: 2.417

2.  Effect of catheter ablation on the left ventricular mass index and other echocardiograph parameters in atrial fibrillation patients: comparison with antiarrhythmic drug treatment.

Authors:  Ki-Hun Kim; Jin Oh Na; Gi-Byoung Nam; Eun-Sun Jin; HyungOh Choi; Sung-Hwan Kim; Kee-Joon Choi; You-Ho Kim
Journal:  J Echocardiogr       Date:  2010-10-05

Review 3.  Electrophysiological and molecular mechanisms of paroxysmal atrial fibrillation.

Authors:  Stanley Nattel; Dobromir Dobrev
Journal:  Nat Rev Cardiol       Date:  2016-08-04       Impact factor: 32.419

4.  Automatic segmentation of the left atrium from MR images via variational region growing with a moments-based shape prior.

Authors:  Liangjia Zhu; Yi Gao; Anthony Yezzi; Allen Tannenbaum
Journal:  IEEE Trans Image Process       Date:  2013-09-16       Impact factor: 10.856

5.  PATH OPTIMIZATION AND CONTROL OF A SHAPE MEMORY ALLOY ACTUATED CATHETER FOR ENDOCARDIAL RADIOFREQUENCY ABLATION.

Authors:  Jennifer H Wiest; Gregory D Buckner
Journal:  Rob Auton Syst       Date:  2015-03-01       Impact factor: 3.120

Review 6.  Is pulmonary vein isolation still the cornerstone in atrial fibrillation ablation?

Authors:  T Jared Bunch; Michael J Cutler
Journal:  J Thorac Dis       Date:  2015-02       Impact factor: 2.895

7.  Hybrid therapy with right atrial catheter ablation and previously ineffective antiarrhythmic drugs for the management of atrial fibrillation.

Authors:  Abraham G Kocheril; Hugh Calkins; Arjun D Sharma; Daniel Cher; Harrison A Stubbs; Jon E Block
Journal:  J Interv Card Electrophysiol       Date:  2005-04       Impact factor: 1.900

8.  Variation of the size of pulmonary venous ostia during the cardiac cycle: optimal reconstruction window at ECG-gated multi-detector row CT.

Authors:  Sang Il Choi; Joon Beom Seo; Seong Hoon Choi; Soo-Hyun Lee; Kyung-Hyun Do; Sung Min Ko; Jin Seong Lee; Jae-Woo Song; Koun-Sik Song; Kee-Joon Choi; You-Ho Kim; Tae-Hwan Lim
Journal:  Eur Radiol       Date:  2005-03-09       Impact factor: 5.315

9.  A Kalman Filtering Perspective for Multiatlas Segmentation.

Authors:  Yi Gao; Liangjia Zhu; Joshua Cates; Rob S MacLeod; Sylvain Bouix; Allen Tannenbaum
Journal:  SIAM J Imaging Sci       Date:  2015-04-30       Impact factor: 2.867

10.  A randomized trial comparing effects of radiofrequency and cryoablation on the structural integrity of esophageal tissue.

Authors:  Rudolph F Evonich; David M Nori; David E Haines
Journal:  J Interv Card Electrophysiol       Date:  2007-08-10       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.